Skip to main content

Total Number of Voting Rights and Capital

Written by Customer Service on . Posted in Public Companies.

THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION.Acacia Pharma Group plcCambridge, UK and Indianapolis, US – 11 March 2021, 18:00 CET. As previously announced1, Acacia Pharma Group plc launched a capital increase in cash within the authorized capital. The gross amount of this capital increase amounted to EUR 27 million via an issue of 10,000,000 new shares at an issue price of EUR 2.70 per share. The capital increase was achieved through an exempt accelerated private placement with international qualified and/or institutional investors with the composition of an order book (an accelerated bookbuilding). Additionally, 116,000 shares were issued in January and February 20212 to satisfy the exercise of options granted under the Company’s Enterprise Management Incentive Share Option Plan at an exercise price of GBP 2.00 per share.Press release of 19 February 2021 – Results of Placing – EUR 27 million Raised to Invest Further in US Launch and Commercialization ActivitiesPress releases of:20 Jan 2021 – Issue of Equity on Exercise of Options / Vesting of Performance Share Awards04 Feb 2021– Issue of Equity on Exercise of Options / Vesting of Performance Share Awards12 Feb 2021 – Issue of Equity on Exercise of Options / Vesting of Performance Share Awards26 Feb 2021 – Issue of Equity on Exercise of Options / Vesting of Performance Share AwardsOf the 5,274,961 options and RSUs currently outstanding, 1,592,518 will be satisfied through the transfer of shares already issued and admitted to trading and held within the Acacia Pharma Group plc Employee Benefit Trust.ContactsAcacia Pharma Group plc
The Officers’ Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United Kingdom
Company number 9759376About Acacia PharmaAcacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.Acacia Pharma’s first product, BARHEMSYS® (amisulpride injection) is marketed in the US for the management of postoperative nausea & vomiting (PONV).BYFAVO™ (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved and launched in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market.APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centered in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.www.acaciapharma.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.